Key Takeaways
- Sort alcohol use disorder options into three tiers: FDA-approved medications like naltrexone and acamprosate, off-label choices like topiramate and gabapentin, and investigational treatments like GLP-1 drugs and psilocybin 7.
- Oral naltrexone has moderate-strength evidence with a number needed to treat of 11 to prevent return to heavy drinking, making it a strong first conversation with a primary care doctor 5.
- Medication choice depends on specifics: recent opioid use rules out naltrexone, kidney function limits acamprosate, and your drinking goal shapes which option fits your life 2, 6.
- A prescription changes biology, not Thursday night. Pair any medication with counseling, follow-up, and medically supervised withdrawal when heavy daily drinking is in the picture 1, 8.
The real shift in alcohol use disorder care
If you’ve been searching for new treatments for alcoholism, here’s the honest headline: there isn’t one miracle pill, shot, or mushroom that fixes everything. What’s actually changed is that medications for alcohol use disorder finally work well enough, and are available enough, that your care can be matched to you instead of the other way around.
That’s the real shift. Historically, options were more limited. Today, three FDA-approved medications sit alongside behavioral care, and several second-line options give doctors more room to tailor a plan 6. NIAAA notes that AUD medications can be prescribed in primary care and do not require specialized addiction licensing, which means help is closer than most people think 9.
You still need a plan, not just a prescription. The pages ahead sort what’s proven from what’s promising, so you can tell the difference between a real option and a headline.
What counts as a ‘new’ treatment for alcoholism right now?
When you type “new treatments for alcoholism” into a search bar, you’re probably picturing something recent and dramatic: a weight-loss shot that quiets cravings, a guided mushroom session, a brain stimulation device. Some of that research is real. Most of it is early.
Here’s a more useful way to think about “new.” There are three categories worth separating in your head:
- Medications that have been around for years but are increasingly prescribed in primary care, not only in specialty settings 9. Oral naltrexone, the once-a-month naltrexone shot, and acamprosate fall here 2.
- Options doctors increasingly reach for when the first-line choices don’t fit, like topiramate and gabapentin 6.
- Genuinely investigational treatments getting a lot of press, including GLP-1 drugs like semaglutide and psilocybin-assisted therapy, where early signals look interesting but the studies are small and the placebo responses are big 7.
Sorting what’s proven from what’s promising is how you avoid chasing a headline instead of a plan.
A three-tier way to read the news on AUD treatment
Tier 1, Tier 2, Tier 3: how to tell evidence from hype
When a friend sends you an article about a weight-loss drug quieting cravings, or a podcast raves about a psychedelic breakthrough, it helps to have a simple way to sort what you’re hearing. Think of alcohol use disorder treatments in three tiers, based on how much evidence actually backs them.
Tier 1 is the FDA-approved shelf. Three medications live here: naltrexone (as a daily pill or a once-a-month shot), acamprosate, and disulfiram 2. These have been studied in large trials, carry formal approval for alcohol use disorder, and show up in the main clinical guidelines doctors follow 6. An AHRQ systematic review of outpatient care found moderate-strength evidence for oral naltrexone and acamprosate specifically 5. If you want something your primary care doctor can prescribe today with real data behind it, this is where to start.
Tier 2 is the guideline-suggested or off-label shelf. Topiramate and gabapentin aren’t FDA-approved for alcohol use disorder, but the VA/DoD guideline recommends topiramate alongside naltrexone and lists gabapentin as a suggested second-line option 3. NIAAA notes the same, especially for people who can’t take or don’t respond to Tier 1 medications 6. These are real tools, used often, with slightly thinner evidence.
Tier 3 is the “watch this space” shelf. Semaglutide and other GLP-1 drugs, psilocybin-assisted therapy, and ketamine are all being studied for alcohol use disorder. Early trials show medium-to-large effects on some outcomes, but samples are small and placebo responses are substantial 7. Interesting? Yes. Something to build your recovery plan around today? Not yet.
Tier 1: FDA-approved medications that actually move the needle
Oral naltrexone: the daily pill with the strongest everyday evidence
If you asked a primary care doctor today what to try first for alcohol use disorder, the answer is often oral naltrexone. It’s a once-a-day pill, usually 50 mg, that blunts the reward you get from drinking. You can still physically drink on it, but the feeling that one pour pulls you toward six tends to quiet down. That’s the point.
The strongest everyday evidence comes from an AHRQ systematic review of outpatient care in adults. For oral naltrexone 50 mg, the estimated number needed to treat was 18 to prevent a return to any drinking and 11 to prevent a return to heavy drinking 5. In plain terms: treat 11 people with oral naltrexone, and roughly one more person avoids returning to heavy drinking than would have on placebo. That’s a real, measurable effect for a pill that primary care can prescribe 9.
What this means for you: oral naltrexone is a reasonable first conversation if you drink opioids out of your life (it blocks them, so active opioid use is a hard stop) and your liver tests are in range 2. Nausea and headache are the common early side effects, and most people who get them see them fade within the first week or two.
Extended-release injectable naltrexone: the once-a-month shot
Same medication, different delivery. The shot form of naltrexone is given once a month in a clinic 8. If you’ve ever forgotten a pill for three days and watched a plan unravel, you already understand why this format matters. One decision a month, not thirty.
The FDA describes extended-release injectable naltrexone as a monthly medication for alcohol or opioid dependence, meant to sit inside a broader program with counseling and support, not stand alone 8. A generic version is now available, which may ease the cost conversation with your insurance 8.
The practical fit: this format often makes sense if daily pills have been a sticking point, if someone close to you has watched adherence slip during stressful weeks, or if the structure of a scheduled appointment is itself part of your recovery plan. The same opioid caution applies — any recent opioid use needs to be worked out with your clinician before the first dose 2.
Acamprosate: support for staying stopped after withdrawal
Acamprosate is the quieter medication in this group, and it does a different job. Instead of blunting reward from drinking, it helps settle the long tail of discomfort that follows quitting — the restless, keyed-up, something-is-off feeling that can linger for weeks after your last drink. NIAAA describes it as a medication intended to support abstinence after withdrawal 6.
You take it as pills three times a day, which is the main adherence catch. The AHRQ review found moderate-strength evidence that acamprosate helps people stay off alcohol compared with placebo 5. Because it’s cleared by the kidneys rather than the liver, it’s often a better fit than naltrexone if your liver is already stressed, though it needs dose adjustment or avoidance in significant kidney disease 2.
What this means for you: acamprosate works best when you’ve already stopped drinking and want help staying there.
Disulfiram: an older option that still fits a few people
Disulfiram is the oldest medication on this list and the most straightforward: if you drink while taking it, you get sick — flushing, nausea, a racing heart. The deterrent is the whole point. It’s FDA-approved for alcohol use disorder and still listed in the main clinical guides 2.
The honest caveat: the AHRQ review found insufficient well-controlled evidence to establish disulfiram’s efficacy versus placebo in outpatient settings 5. It tends to work best for a specific person — someone who is strongly committed to abstinence. For most people today, naltrexone or acamprosate is a better first conversation. Disulfiram is a tool, not a first move.
Tier 2: off-label and second-line options doctors use more now
Topiramate and gabapentin: when first-line medications are not the fit
Not everyone lines up neatly behind naltrexone or acamprosate. Maybe you can’t take naltrexone because of ongoing opioid use. Maybe you tried acamprosate and the three-times-a-day schedule fell apart in week two. Maybe your liver isn’t a good match for one, and your kidneys aren’t a good match for the other. This is where Tier 2 earns its spot.
Topiramate is a seizure and migraine medication that calms the drive to drink in some people. The VA/DoD guideline actually recommends it alongside naltrexone as a first-choice option, which is a stronger stance than you’ll see in many other guides 3. The AHRQ systematic review found moderate-strength evidence for topiramate in reducing drinking in outpatient care 5. The tradeoff is tolerability — some people get tingling, trouble finding words, or appetite changes, so doses are started low and raised slowly.
Gabapentin, also used for nerve pain and seizures, shows up as a suggested second-line option in both the VA/DoD guideline and NIAAA’s resources, particularly for people with lingering sleep problems or anxiety during early recovery 3, 6. The AHRQ review rated the evidence for gabapentin as low strength, so for the right person it fills a real gap but with less certainty than topiramate 5. Neither is a magic swap — they’re options your doctor can reach for when Tier 1 isn’t the fit.
Tier 3: emerging treatments worth watching, not banking on
Semaglutide and GLP-1 drugs: is Ozempic really a treatment for drinking?
You’ve probably seen the stories. Someone starts a weight-loss shot and suddenly the glass of wine after work loses its pull. Friends notice. Reddit threads pile up. Then a headline asks whether Ozempic is the next big thing for alcohol use disorder.
Here’s the honest read. Semaglutide and other GLP-1 receptor agonists are being studied for alcohol use disorder, and early trials show interesting signals on some drinking outcomes 7. That’s genuinely interesting. It’s also early. The same review flags robust placebo responses, small sample sizes, and short follow-up windows, which is a polite way of saying the signal could shrink as bigger studies come in 7.
What this means for you: no GLP-1 drug is FDA-approved for alcohol use disorder 2. If you’re already taking one for diabetes or weight and notice your drinking has eased, that’s worth telling your doctor. If you’re thinking of asking for one specifically to stop drinking, know that you’d be reaching past medications with much stronger evidence to get there.
Psilocybin-assisted therapy: what the 2022 trial actually showed
Psilocybin is the compound in certain mushrooms. In a 2022 randomized trial, researchers gave two doses of psilocybin to adults with alcohol use disorder, paired it with structured psychotherapy, and compared the results to an active placebo plus the same psychotherapy. The headline number: heavy-drinking days ran at 9.7% in the psilocybin group during follow-up versus 23.6% in the placebo group, a mean difference of 13.9 percentage points 4.
That’s a meaningful result for a well-designed study. It’s also one trial of 93 adults, conducted inside a careful psychotherapy program with trained guides, screening, and follow-up 4. It doesn’t translate to microdosing at home, buying mushrooms from a friend, or expecting a weekend retreat to carry you through recovery. The research review covering novel treatments reaches the same conclusion: promising signals, small samples, strong placebo effects, and more study needed before this becomes standard care 7.
If you’re drawn to this because talk therapy hasn’t moved the needle, that’s a real feeling worth taking seriously. The current answer is that psilocybin-assisted therapy is investigational, not available as routine treatment, and never a safe substitute for medically supervised care if you’re drinking heavily now.
Ketamine and other early-stage approaches
Ketamine shows up in the same conversation. It’s an anesthetic now being studied for alcohol use disorder alongside therapy. The novel-treatments review groups it with psilocybin and GLP-1 drugs as approaches with early signals, limited trial sizes, and open questions about who benefits and for how long 7.
Other early-stage work — different receptor targets, digital tools that pair medication with coaching, precision approaches that match treatment to genetics — is moving, but none of it has crossed into standard care. If a clinic markets ketamine infusions or an “advanced” protocol as a solution for drinking, ask what trial evidence they’re relying on and what the plan is for the months after the treatment ends.
How a clinician actually chooses between these medications
A good first appointment doesn’t start with “here’s a prescription.” It starts with questions, because the medication that fits you depends on specifics about your body, your drinking, and your life.
Opioid use comes up first. Any recent opioid use — including prescription pain medication — rules out naltrexone, in both the pill and shot form, until that’s sorted out 2. Your liver and kidneys come up next. Naltrexone is cleared by the liver, so significantly elevated liver tests push the conversation toward acamprosate. Acamprosate is cleared by the kidneys, so reduced kidney function pushes it back the other way 2.
Then the clinician asks about your goal. Are you trying to cut down, or are you ready to stop completely? Naltrexone can work for both. Acamprosate is designed for people who have already stopped and want help staying stopped 6. Disulfiram only makes sense if abstinence is the goal 2.
Daily life matters too. If three pills a day will fall apart by Thursday, the monthly shot or a once-daily option is a better bet 8. If Tier 1 medications don’t fit — because of side effects, kidney or liver issues, or ongoing anxiety and sleep problems — topiramate or gabapentin become reasonable next moves 3, 6. The point isn’t to find the “best” medication. It’s to find the one you’ll actually take.
Why medication alone usually underdelivers
Here’s the part the headlines skip. A prescription changes your biology, not your Thursday night. Naltrexone can quiet the pull of the first drink, acamprosate can smooth the weeks after you stop, but neither one knows that your sister’s wedding is coming up, or that you still haven’t told anyone at work what’s going on. That’s the gap counseling fills.
The FDA says it plainly about the monthly naltrexone shot: it’s meant to sit inside a comprehensive program with psychosocial support, not stand alone 8. SAMHSA’s clinical manual makes the same case across every FDA-approved AUD medication — pair it with counseling and ongoing follow-up, or you leave results on the table 1. NIAAA’s framework treats behavioral care and medication as the two legs of evidence-based treatment, not alternatives 9.
A medication is a tool. The plan is what makes it work.
Where safe withdrawal management fits in
Before any medication conversation gets interesting, there’s a question that comes first: how much are you drinking right now, and what happens when you stop? Alcohol withdrawal is one of the few substance withdrawals that can be life-threatening. Shakes, sweats, racing heart, and anxiety are the mild end. Seizures and delirium tremens are the end that lands people in an emergency room.
Here’s the practical piece. The three FDA-approved AUD medications fit different moments in that process. Naltrexone can be started once withdrawal is settled and any opioids are out of the system 2. Acamprosate is designed for after you’ve stopped, to help you stay there 6. SAMHSA’s clinical guidance treats medically supervised withdrawal and pharmacotherapy as pieces of the same continuum, not separate decisions 1. If you’re drinking heavily now, safe withdrawal management is the first step, not something to skip past to get to the medication conversation.
Connecting new medications to ongoing care
A prescription is a start, not a plan. The medications in Tier 1 and Tier 2 work best when they’re part of something larger — a stepped path that meets you where you are and keeps meeting you as things shift.
For most people, that path has recognizable steps. If heavy daily drinking is in the picture, medically supervised detox comes first, where withdrawal can be managed safely and medication conversations can begin 1. From there, care often steps down through a partial hospitalization program (several hours a day, most days), an intensive outpatient program (fewer hours, fewer days), standard outpatient visits, and aftercare or alumni support. At Pacific Crest Trail Detox, that continuum also includes ongoing outpatient support through our partner program, Oregon Trail Recovery. Medications can be started, continued, or changed at any point along the way 1, 9.
The reason this matters: NIAAA names behavioral healthcare and FDA-approved medications as the two legs of evidence-based treatment, not alternatives you pick between 9. The counseling teaches you what to do on a hard Tuesday. The medication makes the hard Tuesday a little less loud.
Questions to bring to your doctor or treatment team
Walking into a first appointment with a short list beats trying to remember everything in the moment. These questions help you get past the pamphlet and into a real plan.
- Based on how I’m drinking now, do I need medically supervised withdrawal before we start a medication 1?
- Which FDA-approved option fits me best given my liver, kidneys, and any opioid use 2?
- If naltrexone or acamprosate isn’t a good fit, would topiramate or gabapentin be reasonable to try 3, 6?
- Is my goal cutting back or stopping completely, and does that change the medication you’d recommend 6?
- What counseling or program will you pair this prescription with, and how will we track whether it’s working 1?
- How often will we check in during the first few months, and what signals a change in plan 9?
Write the answers down. A good team will welcome the questions.
A warm next step if you’re weighing your options
If you’ve read this far, you’re already doing the hardest part: looking honestly at what might help. The medications are real. The research on what’s next is moving. And the plan that actually works usually starts with a conversation, not a prescription.
If daily or heavy drinking is in the picture, medically supervised detox is the safest first step, and it opens the door to the medication and counseling choices that follow. Pacific Crest Trail Detox serves the Portland metro from Milwaukie, Oregon, and welcomes out-of-state clients. Continued outpatient support is available through our partner program, Oregon Trail Recovery. Calls are confidential and HIPAA-protected. We want to be your last treatment experience, whether we’re your first detox or your fifth.
Check Coverage for Alcohol Detox Care
Find out whether your plan may help cover medically supervised alcohol detox and treatment.
Frequently Asked Questions
Is there a new pill or shot that cures alcoholism?
No. There’s no medication that cures alcohol use disorder. What’s real: three FDA-approved medications — naltrexone (pill or monthly shot), acamprosate, and disulfiram — can meaningfully reduce drinking when paired with counseling and follow-up 2, 1. They’re tools that make recovery more possible, not a one-time fix.
Can Ozempic or other GLP-1 drugs be used to treat alcohol use disorder?
Not as approved treatment. Early trials of semaglutide and other GLP-1 drugs show interesting signals for drinking outcomes, but samples are small and placebo responses are strong 7. No GLP-1 is FDA-approved for alcohol use disorder 2. If you’re on one and notice drinking has eased, tell your doctor.
How do doctors decide between naltrexone, acamprosate, and other AUD medications?
Doctors weigh opioid use (which rules out naltrexone), liver and kidney function, your goal (cutting back versus staying stopped), and whether you can keep up with daily pills 2. Naltrexone works for both reduction and abstinence; acamprosate helps you stay stopped after withdrawal 6. If Tier 1 options don’t fit, topiramate or gabapentin may 3.
Is it safe to stop drinking on my own if I start one of these medications?
If you’ve been drinking heavily and daily, no. Alcohol withdrawal can cause seizures and delirium tremens and sometimes turns life-threatening. Medically supervised withdrawal comes first; medications like naltrexone or acamprosate are started safely after that 1, 2. A clinician should make the call about where to begin based on how much and how often you drink.
Does psilocybin-assisted therapy really work for alcohol use disorder?
One well-designed 2022 trial of 93 adults showed meaningful reductions in heavy-drinking days when psilocybin was paired with structured psychotherapy 4. It’s a real signal, not a cure. The research is still early, samples are small, and this is not available as routine care 7. Microdosing or unsupervised use is not the same thing.
Where does medical detox fit if medications are available in primary care?
Primary care can prescribe AUD medications without a specialty license 9. But if you’re drinking heavily every day, withdrawal needs medical supervision first because it can be dangerous 1. Medical detox handles that safely, then connects you to the medication and counseling pieces that follow. It’s the starting point, not a detour.
References
- TIP 49: Incorporating Alcohol Pharmacotherapies into Medical Practice. https://www.samhsa.gov/resource/ebp/tip-49-incorporating-alcohol-pharmacotherapies-medical-practice
- Medication for the Treatment of Alcohol Use Disorder. https://library.samhsa.gov/sites/default/files/sma15-4907pocketguid.pdf
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. https://healthquality.va.gov/HEALTHQUALITY/guidelines/MH/sud/VADODSUDCPGPocketCard.pdf
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC9403854/
- Updated Systematic Review Examines Pharmacotherapy for Adults With Alcohol Use Disorder in Outpatient Settings. https://www.ahrq.gov/news/newsroom/press-releases/alcohol-use-disorders.html
- Recommend Evidence-Based Treatment: Know the Options. https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/recommend-evidence-based-treatment-know-options
- Pharmacological interventions for alcohol use disorder: novel insights from recent clinical trials. https://pmc.ncbi.nlm.nih.gov/articles/PMC13132032/
- A Step Forward in the Treatment of Opioid and Alcohol Dependence with Dr. Iilun Murphy and Dr. Marta Sokolowska. https://www.fda.gov/drugs/news-events-human-drugs/step-forward-treatment-opioid-and-alcohol-dependence-dr-iilun-murphy-and-dr-marta-sokolowska
- Alcohol Use Disorder: From Risk to Diagnosis to Recovery. https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/alcohol-use-disorder-risk-diagnosis-recovery


